ResMed enters $450M accelerated share repurchase with Citibank

RESMED INC

ASR agreement with Citibank to repurchase $450M of common stock, funded by MatrixCare sale proceeds and cash.
Payment of $450M on Sept 3, 2026; initial delivery of 80% of $450M / Sept 2 closing price.
Final settlement expected December 2026 based on volume-weighted average price, with potential adjustments.
Repurchase under existing 20M share authorization from Feb 2014; contemplated in FY27 guidance.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.